Hawaii Biotech To Perform West Nile Vaccine Clinical Trials

Armen Hareyan's picture
Advertisement

West Nile Vaccine Clinical Trials

Hawaii Biotech has been notified by FDA that it may proceed to initiate a 24 patient safety study in healthy human volunteers with its recombinant, subunit West Nile vaccine.

Advertisement

The trial will be conducted at a single site in Hawaii, which the company currently expects to start in April 2008, pending successful completion of financing sufficient funding to complete the trial. Depending on the actual start date, results of the trial may be available by the end of 2008.

HBI develops subunit vaccine candidates that have been shown to elicit protective immune responses in animal efficacy models for diseases such as West Nile, dengue, influenza, Ebola, malaria and tick-borne encephalitis.

"The West Nile vaccine will be the first candidate to enter clinical trials for Hawaii Biotech. This is a substantial milestone for the company as it is a novel vaccine candidate with which the FDA has had little experience. Receiving this notification from the FDA that we may proceed to human clinical trials is the first step in proving our technology in a clinical setting and to the scientific community," said Dr. Carolyn Weeks-Levy, President and CEO of HBI.

Currently there is no vaccine for the prevention of West Nile disease in humans; a disease that has caused over 25,000 cases of disease and over 1000 deaths since the virus was introduced in the U.S. in 1999.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.
Advertisement